The increase in price target by a reputable analyst like Brian Abrahams signals a strong vote of confidence in Neumora Therapeutics' future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price, as market participants often react to analyst upgrades and revised price targets.